Last reviewed · How we verify
Mannosylstreptomycin — Competitive Intelligence Brief
unknown
Streptomycin B
Infectious Disease
Live · refreshed every 30 min
Target snapshot
Mannosylstreptomycin (Streptomycin B). Mannosylstreptomycin works by binding to the 30S subunit of the bacterial ribosome, preventing the attachment of transfer RNA and thereby inhibiting protein synthesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mannosylstreptomycin TARGET | Streptomycin B | unknown | Streptomycin B |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Streptomycin B class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mannosylstreptomycin CI watch — RSS
- Mannosylstreptomycin CI watch — Atom
- Mannosylstreptomycin CI watch — JSON
- Mannosylstreptomycin alone — RSS
- Whole Streptomycin B class — RSS
Cite this brief
Drug Landscape (2026). Mannosylstreptomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/streptomycin-b. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing